XERS
Xeris Q2 2026 revenue exceeds $92M
Xeris Biopharma reported $92.1M in Q2 2026 revenue, up 29% year-over-year, driving a revision of full-year guidance to $385M-$390M as Recorlev sales surged.
XERS news
Latest 3 stories · newest Aug 6, 2026
XERS
Xeris Appoints John Shannon as New Board Chair and Adds Dr. Nerissa Kreher
Xeris Biopharma announced CEO John Shannon will assume the role of Chair of the Board following a transition by Marla Persky. The company also appointed Dr. Nerissa Kreher, adding a new executive with rare disease expertise to strengthen its biopharmaceutical leadership.
XERS
Xeris exchanges $23M convertible notes for cash and stock
Xeris Biopharma agreed to retire approximately $23 million of 8.00% Convertible Senior Notes due 2028 through private exchanges, reducing annual interest expenses by roughly $2 million. The transaction involves cash payment plus approximately 4.6 million common shares, strengthening the company's ba…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same XERS feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/XERS/newsSTART FREE